We have evaluated Roche Diagnostics' RIA-CEA and Abbott Diagnostics' EIA-CEA methods for precision, normal reference interval, concordance, and correlation of malignant disease with increase in carcinoembryonic antigen (CEA) in plasma. In examining concordance, we used data on 138 patients with primary carcinomas of the breast, colon, lung, or pancreas, each further classified by extent of dissemination. We find the two methods to be comparably precise. The respective upper reference limits of normal for the Roche and Abbott methods were determined to be 5.0 /L and 4.6 g/L. The regression equation for a log transformation of the 177 data points is y = 0.966x +0.03, where x = Roche andy = Abbott, with a correlation coefficient of 0.948. According to the criteria we used, the concordance was 78.7%. The largest discordance was observed in widely disseminated disease states and in cancers of the colon and pancreas. Paired data analysis of discordance indicated greater increases in apparent CEA by the Abbott method in most colon cancers with liver involvement; six of the eight discordant pancreatic cancers had higher Roche-CEA values. CEA heterogeneity and the role of the liver in CEA metabolism appear to contribute to the observed differences. We show why the two methods should not be used interchangeably, and that baseline values for CEA must be established for each method. 
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enzyme immunoassay
The role of carcinoembryonic antigen (CEA) as a "tumor marker" in the management of cancer has been studied extensively (1) (2) (3) (4) (5) (6) . Serially measured CEA concentrations correlate with response to adjuvant therapy.
Increases in plasma CEA concentrations during and after treatment are often indicative of recurrent or progressive disease; declining concentrations are associated with effective therapy (7) (8) (9) (10) . Values for CEA measured pre-operatively may have prognostic significance (11-13); those obtained postoperatively, and sequentially thereafter, are used as indicators of completeness of the resection and of recurrence of disease after surgery (14, 15) .
Until 1980, only Roche Diagnostics' RIA procedure for CEA was used in the United States. Since then, the U.S.
Food and Drug Administration has approved use of Abbott
Diagnostics' radioimmunoassay (RLA) (not evaluated in this study) and enzyme immunoassay (EIA) methods for CEA. anti-CEA antibody raised in the guinea pig and goat antibody to CEA conjugated to peroxidase. Both anti-CEA antibodies were raised against CEA purified from a colon cancer in tissue culture. In the Roche method, plasma is prepared for radioimmunoassay by extraction with perchloric acid, followed by dialysis, or by column-chromatographic separation.
In the Abbott methods, extraction at 70 #{176}C is used.
CEA is one of the several tumor markers used in monitoring chemotherapeutic and radiotherapeutic response of various cancers. Thousands of patients currently are being monitored by sequential measurements of CEA. Intercomparability of the sequential CEA data clearly is essential to the clinical decision-making as to the patient's course of treatment.
Our institution is primarily a cancer-treatment center, and most of our patients have been clinically evaluated at other medical centers and arrive here bringing records of laboratory data. Other patients, although seen here initially, will wish to have their cases followed and treated by a local physician more convenient to their homes. Thus, more than one health-care facility may be involved with a patient, so it is essential to be able to compare information obtained with these two current CEA methods. Ideally, the two assays would provide the same information to the clinician. The present study was intended to see how well results by the two assays compare and how well the clinical picture correlates with these laboratory data. ly, dispensed in 1-mL aliquots into 12 x 75 mm polypropylene tubes, and stored at -20 #{176}C. Aliquots were thawed as needed, at the time of assay. A positive control (human CEA in calf serum) was provided by Abbott Diagnostics.
Materials and Methods

Specimen
Statistics.
In the reference-interval study we used the mean ± 2 standard deviations as the 95% confidence interval.
Mean values were compared by Student's i-test. A log transformation was applied to the CEA data before linear regression. We used a technique of exploratory data analysis, "parallel schematic plots," in visualizing the distribution of the data points (19).
Results
Comparison
of CEA assay precision. Using our qualitycontrol human plasma pools, we evaluated the precision of the Roche and Abbott CEA procedures. Table 3 summarizes the results of this study. Because we were already evaluating the Roche reference interval when the present comparison study was begun, the sample population for it is larger.
The 95% confidence limit for the Roche assay was 0-4.9 p.g/L for non-smokers, 0-5.0 g/L for the combined population of smokers and non-smokers.
For the Abbott assay, the ranges for non-smokers and the combined populations were virtually identical: 0.1-4.5 and The Figures 2 and 3 show parallel box-plot analyses of the CEA data, the median being used as a measure of central tendency. These represent a general overview of the data, not a paired-data analysis. Absolute sensitivity cannot be inferred from the parallel box plots. To calculate box-plot information, each set of data is first arranged in descending numerical order of CEA concentration. The "box" area represents the middle 50% of the data, from the 1st quartile limit to the 3rd quartile limit, for each patient population.
As shown in Figure 2 , the five horizontal lines (starting with the one nearest the bottom) denote the minimum CEA concentration, the calculated 1st quartile (0-25% of the data), the calculated median (0-50% of the data), the calculated 3rd quartile (0-75% of the data), and the maximum CEA value in the data set. Abbott EIA had a greater 3rd quartile range than Roche RIA for breast cancer with distant metastasis and colon cancer with distant metastasis. These differences in the 3rd quartil,e distribution may be of no clinical significance when 60-75% of the values exceed the normal range. For colon cancer with no metastasis, where both medians are well within the normal ranges, an extended 3rd quartile (Roche) may reflect a greater sensitivity.
Comparing "no metastasis" with "distant metastasis" categories for each primary site should show how well each CEA assay detects metastasis.
We compared the percentages of CEA values that were above the normal reference limit in patients with no metastasis or local metastasis with those for patients with distant metastasis; the results are shown in Table 4 . In the breast-, colon-, and lung-cancer categories the percentages of CEA values exceeding the upper limits of normal were much greater for disseminated than for local disease. However, within the pancreaticcancer group a larger fraction of patients with local disease had above-normal values for CEA as compared with those with metastatic disease. Discordance. (Table 5) , we found an additional 20 discordant pairs.
Although both values were above normal, the discrepancy between the results was too large to be attributed to total 
